Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study
Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study
复制标题
DOI：
10.1016/j.clgc.2019.07.006
复制
发表时间：
2019-10-01
影响因子：
3.2
通讯作者：
Ohyama, Chikara
中科院分区：
文献类型：
--
作者：
Konishi, Sakae;Hatakeyama, Shingo;Ohyama, Chikara
我们验证了国际转移性肾癌数据库联盟(IMDC)一线治疗转移性肾癌患者的预后模型的特点。在一线接受阿昔替尼治疗的患者中，IMDC预后模型是活跃的。C-反应蛋白水平和阳性危险因素的数量相结合可以预测IMDC中危患者的预后。背景：该研究的目的是在临床实践中验证国际转移性肾癌数据库联盟(IMDC)预后模型的特点。患者和方法：我们对2008年10月至2019年2月期间接受阿昔替尼一线治疗的143例转移性肾癌患者进行了回顾性评估。总生存期(OS)根据IMDC预后模型进行评估。我们调查了中等风险组的组内异质性，并根据异常的C-反应蛋白(CRP)水平对这些患者进行了分类。采用反向治疗概率加权(IPTW)调整的COX回归分析来评估在IMDC中危组患者中应用CRP-OS风险模型的效果。结果：IMDC中危和中危患者的OS差异有统计学意义，而IMDC中危和中危患者的OS差异无统计学意义。有2个危险因素且CRP=0.3 mg/dL的中危IMDC组患者的预后显著短于有1个危险因素或2个危险因素且有CRP的患者
We validated the characteristics of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model in patients with metastatic renal-cell carcinoma treated with axitinib in the first-line setting. The IMDC prognostic model was active in patients who received axitinib in the first-line setting. The combination of C-reactive protein value with the number of positive risk factors might predict prognosis in patients in the IMDC intermediate-risk group.Background: The objective of the study was to validate the characteristics of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model in patients treated with first-line axitinib in clinical practice. Patients and Methods: We retrospectively evaluated 143 patients with metastatic renal-cell carcinoma who were treated with axitinib as the first-line therapy between October 2008 and February 2019. Overall survival (OS) was evaluated according to the IMDC prognostic model. We investigated the intragroup heterogeneity in the intermediate-risk group and divided these patients according to abnormal C-reactive protein (CRP) levels. An inverse probability of treatment-weighted (IPTW)-adjusted Cox regression analysis was performed to evaluate the effects of the CRP-risk model of OS in the patients in the IMDC intermediate-risk group. Results: A significant difference in OS was observed in patients in the IMDC intermediate- and poor-risk group, although no significant difference was observed between the IMDC favorable- and intermediate-risk group. Significantly shorter prognosis was observed in patients in the IMDC intermediate-risk group who had 2 risk factors and CRP >= 0.3 mg/dL (inter-high group) than in those with 1 risk factor or 2 risk factors with CRP